CRMD - NASDAQ

CorMedix Inc.

CorMedix Inc.

CRMD·NASDAQ

$8.23

+0.73%
HealthcareBiotechnology

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$645.66M
EPS2.2500
P/E Ratio3.66
Earnings Date08/06/2026
175.05M
Operating Cash Flow
-446%
3Y-819.0%
5Y-897.0%
10Y-886.0%
-308.43M
Investing Cash Flow
-1553%
3Y+8215.0%
5Y-4253.0%
10Y-2801.0%
238.45M
Financing Cash Flow
806%
3Y+1232.0%
5Y+495.0%
10Y+3262.0%
CRMD

CorMedix Inc. Cash Conversion Engine

CRMD · NASDAQ
Net Income163.06M
Depreciation & Amortization0.00
Stock-Based Compensation0.00
Change in Working Capital7.27M
Others4.72M
Capital Expenditures-2.26M
Free Cash Flow172.79M

Cash Flow Quality Analysis

FCF Conversion Rate

106.0%

Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.

CapEx Intensity

1.3%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+440.6%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$7.27M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Cash Flow Quality Insight

Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.

CorMedix Inc. Cash Flow Statement

CRMD • NASDAQ

CorMedix Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008
OPERATING ACTIVITIES
Net Income
163.1M
-17.9M
-46.3M
-29.7M
-28.2M
-22M
-16.4M
-26.8M
-33M
-24.6M
-18.2M
-20.5M
-9.1M
-3.4M
-6.7M
-10.9M
-8.1M
-9M
Depreciation & Amortization
0.0
309.8K
70.8K
84.6K
61.9K
128K
73.3K
74.2K
36.9K
25.6K
15.1K
15.1K
5.2K
7K
12.2K
12.2K
9.9K
1M
Change in Deferred Taxes
0.0
0.0
0.0
0.0
0.0
0.0
-579K
-3.1M
-4.6M
0.0
0.0
9.2M
1.5M
0.0
0.0
1.5M
692.7K
0.0
Stock-Based Compensation
0.0
6.1M
5.5M
4.1M
5M
2.5M
2.4M
1.1M
1.7M
1.3M
3.2M
2.2M
1.3M
274.4K
692.4K
1.2M
114.1K
0.0
Other Non-Cash Items
4.7M
284.6K
134.8K
124.4K
115.1K
78.4K
1.4M
3.1M
4.4M
130K
1.8M
2.6M
2.7M
355.7K
0.0
3.9M
5.5M
3.8M
Change in Working Capital
7.3M
-39.4M
2.2M
1.1M
1.8M
-2.6M
-1.9M
1.9M
2.9M
887.5K
598.7K
222.3K
-43.9K
512.4K
-290.1K
615.8K
-302.1K
48.8K
Cash from Operating Activities
175M
-50.6M
-38.4M
-24.4M
-21.2M
-22M
-15.1M
-23.7M
-28.6M
-22.3M
-12.5M
-6.3M
-3.6M
-2.3M
-6.3M
-3.7M
-2.1M
-4.1M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment
-2.3M
-115.7K
-327.3K
-219.4K
-1.4M
-112.6K
-36.6K
-48.9K
-152K
-58.7K
-15.4K
-25.4K
-35.7K
(0.0)
-1.6K
-10.4K
(0.0)
(0.0)
Acquisitions, Net
-308.5M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(12M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
Purchase of Investments
-53M
-26.8M
-77.1M
-31.1M
-15.3M
-8.5M
-14.1M
(0.0)
-13.1M
(0.0)
-23.6M
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
Sale/Maturity of Investments
55.3M
48.1M
60.4M
27.7M
7.6M
16.1M
2.1M
1.6M
23.6M
11.5M
0.0
0.0
1M
0.0
0.0
10.5M
0.0
0.0
Other Investing Items
0.0
0.0
0.0
0.0
0.0
0.0
-12M
1.6M
10.5M
11.5M
-23.6M
0.0
-1M
0.0
-1.6K
-10.5M
0.0
0.0
Cash from Investing Activities
-308.4M
(21.2M)
-17.1M
-3.7M
-9.1M
(7.4M)
-12M
(1.6M)
(10.4M)
(11.4M)
-23.6M
-25.4K
-35.7K
(0.0)
-1.6K
-10.4K
(0.0)
(0.0)
FINANCING ACTIVITIES
Net Issuance of Common Stock
96.5M
18.9M
55.8M
17.8M
41.5M
39.7M
15.2M
22M
18.6M
6.2M
28.5M
0.0
1M
0.0
0.0
10.5M
0.0
0.0
Net Issuance of Debt
144.1M
0.0
0.0
0.0
0.0
0.0
0.0
7.5M
0.0
0.0
0.0
0.0
0.0
1.2M
0.0
0.0
2.8M
3.1M
Cash Paid for Dividends
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-384.3K
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
Other Financing Items
-2.2M
7.4M
89.3K
128.6K
301.9K
411.8K
10.6M
-70.9K
6.8K
863.1K
15.2M
7M
1.6M
-70.2K
0.0
0.0
-539.1K
-141.9K
Cash from Financing Activities
238.5M
26.3M
55.9M
17.9M
41.8M
40.1M
25.8M
29.4M
20.5M
7.1M
43.6M
8.4M
5.2M
1.1M
0.0
10.5M
2.3M
3M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates
-226.8K
-1.7K
2.8K
-8.7K
-12.9K
13.2K
-2K
-7.9K
19.6K
245.0
-16.6K
-46K
-11.4K
0.0
0.0
0.0
0.0
0.0
Net Change in Cash
105.1M
-3.1M
448.4K
-10.2M
11.5M
25.6M
-1.3M
7.2M
2.3M
-3.8M
7.5M
2M
1.5M
-1.1M
-6.3M
6.8M
125.2K
0.0
Cash at Beginning of Period
40.8M
43.8M
43.4M
53.6M
42.1M
16.5M
17.8M
10.4M
8.1M
11.8M
4.3M
2.4M
835.5K
2M
8.3M
1.5M
1.4M
0.0
Cash at End of Period
145.8M
40.8M
43.8M
43.4M
53.6M
42.1M
16.5M
17.6M
10.4M
8.1M
11.8M
4.3M
2.4M
835.5K
2M
8.3M
1.5M
1.4M
Free Cash Flow
172.8M
-50.7M
-38.7M
-24.6M
-22.6M
-22.1M
-15.1M
-23.7M
-28.7M
-22.3M
-12.5M
-6.3M
-3.7M
-2.3M
-6.3M
-3.7M
-2.1M
-4.1M

SEC Filings

CRMD - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 14, 2026
May 14, 2026
2026
View Filing
10-Q

10-Q 2026 Q1

Q1

May 14, 2026
March 31, 2026
2026
View Filing
DEF 14A

DEF 14A 2026

N/A

April 29, 2026
June 23, 2026
2026
View Filing
8-K

8-K 2026

N/A

April 27, 2026
April 27, 2026
2026
View Filing
8-K

8-K 2026

N/A

March 06, 2026
March 06, 2026
2026
View Filing
10-K

10-K 2025 FY

FY

March 05, 2026
December 31, 2025
2025
View Filing
8-K

8-K 2026

N/A

March 05, 2026
March 05, 2026
2026
View Filing
8-K

8-K 2026

N/A

January 08, 2026
January 05, 2026
2026
View Filing
8-K

8-K 2025

N/A

November 12, 2025
November 12, 2025
2025
View Filing
10-Q

10-Q 2025 Q3

Q3

November 12, 2025
September 30, 2025
2025
View Filing
Showing 1 to 10 of 409 filings

Related Guides

Blog Categories

Continue your CRMD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.